Floatz logo

gb1275

Hepatocellular Carcinoma

GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.Phase 1Dormant
C
37/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
65/ 100

Competitive context

521 Active assets in the Hepatocellular Carcinoma cohort.

Asset / SponsorPhaseRating
Adefovir
Bukwang Pharmaceutical
Phase 4BBB
Huaier Granule
Tongji Hospital
Phase 4BBB
Sorafenib
Bayer
Phase 4BBB
Carboplatin
AstraZeneca
Phase 4BB
Theprubicin
RWTH Aachen University
Phase 4BB

View all 50 →

Same molecule, other indications

gb1275 is also rated in:

colorectal cancerDormant
CC
Indicative ·
43 / 100
View asset →
castration-resistant prostate carcinomaDormant
CC
Indicative ·
41 / 100
View asset →
small cell lung carcinomaDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →